Jump to content

Mikhail Blagosklonny

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by GreenC bot (talk | contribs) at 01:42, 16 July 2020 (Rescued 1 archive link. Wayback Medic 2.5). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Mikhail Blagosklonny
Alma materFirst Pavlov State Medical University of St. Peterburg
Scientific career
FieldsAnti-aging medicine, oncology
Institutions

Mikhail Blagosklonny is a scientist who studies cancer and aging. He is an adjunct faculty member at the Roswell Park Cancer Institute in Buffalo, New York.[1]

Career

Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg.[citation needed] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009, when he was appointed professor of oncology at Roswell Park Cancer Institute.[2]

Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.[3] Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.[4]

Rapamycin and aging

Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[5] He advocates for rapamycin use in longevity research.[6]

Editorial activities

Blagosklonny is editor-in-chief of Aging,[7] Cell Cycle,[8] and Oncotarget.[9] In addition, he is associate editor of Cancer Biology & Therapy[10] and a member of the editorial board of Cell Death & Differentiation.[11]

The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,[12] a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals"[13] in July 2015.[12] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.[14]

References

  1. ^ Roswell Park website page on Blagosklonny
  2. ^ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute", Cancer Biology & Therapy, 8 (9): 753–752, May 2009, doi:10.4161/cbt.8.9.8899
  3. ^ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute". Cancer Biology & Therapy. 8 (9): 753–752. May 2009. doi:10.4161/cbt.8.9.8899.
  4. ^ "Mikhail Blagosklonny". Roswell Park Comprehensive Cancer Center. Retrieved 2020-05-01.
  5. ^ Stipp, David (2011). "A New Path to Longevity". Scientific American. 306 (1): 32–39. doi:10.1038/scientificamerican0112-32. PMID 22279832.
  6. ^ "Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015". Retrieved November 20, 2016.
  7. ^ "Editorial Board". Aging. Archived from the original on 2009-01-25. Retrieved 2016-11-20.
  8. ^ "Editorial Board". Cell Cycle. Taylor & Francis. Retrieved 2016-11-20.
  9. ^ "Editorial Board". Oncotarget. Retrieved 2016-11-20.
  10. ^ "Editorial board". Cancer Biology & Therapy. Taylor & Francis. Retrieved 2016-11-20.
  11. ^ "About the journal". Cell Death & Differentiation. Retrieved 2016-11-20.
  12. ^ a b Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. Archived from the original on 20 April 2016. Retrieved 2016-11-20.
  13. ^ Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. Archived from the original on 2 December 2016. Retrieved 19 April 2016.
  14. ^ "Mikhail Blagosklonny's Journal Aging: A Review". Scholarly Open Access. 6 December 2016. Archived from the original on 24 December 2016. Retrieved 17 January 2017.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mikhail_Blagosklonny&oldid=967907996"